Table 4 Univariable and multivariable analysis of significant progression of mSASSS over 2 years
Variable | Univariable analysis | Multivariable analysisa | ||||
|---|---|---|---|---|---|---|
OR | 95% CI | p value | OR | 95% CI | p value | |
Male sex | 0.5 | 0.2–1.5 | 0.223 | |||
Age (years) | 1.1 | 1.0–1.1 | 0.019 | |||
Symptom duration (years) | 1.1 | 1.0–1.1 | 0.064 | |||
BMI (kg/m2) | 0.817 | |||||
< 18.5 | 1.0 | 0.2–5.3 | 0.964 | |||
18.5–22.9 | 1.0 (reference) | |||||
23.0–24.9 | 1.4 | 0.5–4.0 | 0.487 | |||
≥ 25.0 | 1.5 | 0.6–4.2 | 0.408 | |||
Current smoking | 4.1 | 1.7–9.6 | 0.001 | 3.0 | 1.1–7.7 | 0.025 |
HLA B27-positive | 1.3 | 0.3–6.7 | 0.743 | |||
Peripheral arthritis | 0.5 | 0.2–1.6 | 0.269 | |||
Radiographic sacroiliitis | 4.1 | 1.2–14.7 | 0.029 | |||
Presence of syndesmophytes | 5.7 | 2.4–13.8 | < 0.001 | 4.6 | 1.8–11.9 | 0.002 |
BASFI score, per 1 point | 1.0 | 0.8–1.2 | 0.678 | |||
BASDAI score ≥ 4 | 0.9 | 0.7–1.1 | 0.328 | |||
ASDAS-CRP | 0.313 | |||||
Low (< 1.3) | 1.0 (Reference) | |||||
Moderate (< 2.1) | 1.2 | 0.4–3.6 | 0.769 | |||
High (≤ 3.5) | 0.3 | 0.2–1.3 | 0.135 | |||
Very high (> 3.5) | 0.9 | 0.2–3.2 | 0.839 | |||
Increased ESR (≥ 20 mm/h) | 1.1 | 0.5–2.4 | 0.842 | |||
Increased CRP (≥ 5 mg/L) | 1.4 | 0.6–3.3 | 0.431 | |||
Patients on NSAIDs | 0.7 | 0.2–3.1 | 0.716 | |||
Patients on sulfasalazine | 0.7 | 0.3–1.9 | 0.530 | |||
Patients on TNF inhibitors | 1.6 | 0.7–3.7 | 0.298 | |||
Patients on calcium | 3.0 | 0.8–11.3 | 0.097 | |||
Patients on vitamin D | 2.1 | 0.4–10.1 | 0.336 | |||
Low BMD, any site (Z score ≤ − 2.0) | 3.0 | 1.1–8.3 | 0.033 | 3.6 | 1.2–11.2 | 0.028 |